Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nomogram for predicting survival of patients with diffuse large B-cell lymphoma. | Ann Hematol | 2024 | 38411628 | PubTator, text mining | PubMed |
| Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice. | Leuk Lymphoma | 2024 | 38340359 | PubTator, text mining | PubMed |
| Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features. | Blood Adv | 2024 | 38324724 | PubTator, text mining | PubMed |
| Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL. | Cancer Treat Rev | 2024 | 38310754 | PubTator, text mining | PubMed |
| The role of tertiary lymphoid structure and B cells in nasopharyngeal carcinoma: Based on bioinformatics and experimental verification. | Transl Oncol | 2024 | 38295746 | PubTator, text mining | PubMed |
| Multi-omics analysis reveals NNMT as a master metabolic regulator of metastasis in esophageal squamous cell carcinoma. | NPJ Precis Oncol | 2024 | 38291241 | PubTator, text mining | PubMed |
| CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors. | Cancer Immunol Immunother | 2024 | 38280003 | PubTator, text mining | PubMed |
| What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study. | Cancers (Basel) | 2024 | 38275909 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs. | Cancers (Basel) | 2024 | 38275888 | PubTator, text mining | PubMed |
| The characteristics of cerebrospinal fluid tumor microenvironment in a patient with leptomeningeal metastases from cancer of unknown primary. | Genes Dis | 2024 | 38274387 | PubTator, text mining | PubMed |
| Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives. | Blood Cancer J | 2024 | 38272863 | PubTator, text mining | PubMed |
| Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton's Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody-Drug Conjugates. | Bioconjug Chem | 2024 | 38265691 | PubTator, text mining | PubMed |
| MicroRNAs as Potential Graft Rejection or Tolerance Biomarkers and Their Dilemma in Clinical Routines Behaving like Devilish, Angelic, or Frightening Elements. | Biomedicines | 2024 | 38255221 | PubTator, text mining | PubMed |
| Cell-Free DNA as a Biomarker at Diagnosis and Follow-Up in 256 B and T-Cell Lymphomas. | Cancers (Basel) | 2024 | 38254810 | PubTator, text mining | PubMed |
| The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. | Br J Haematol | 2024 | 38247115 | PubTator, text mining | PubMed |
| Deciphering the suppressive immune microenvironment of prostate cancer based on CD4+ regulatory T cells: Implications for prognosis and therapy prediction. | Clin Transl Med | 2024 | 38239097 | PubTator, text mining | PubMed |
| Immune characteristics of kidney transplant recipients with acute respiratory distress syndrome induced by COVID-19 at single-cell resolution. | Respir Res | 2024 | 38238762 | PubTator, text mining | PubMed |
| Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanoma. | Neoplasia | 2024 | 38237304 | PubTator, text mining | PubMed |
Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b. | Leuk Res | 2024 | 38232613 | PubTator, text mining | PubMed |
| Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. | Cancer Cell | 2024 | 38215749 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=15